Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wells Fargo analyst Vik Chopra maintains NeuroPace (NASDAQ:NPCE) with a Overweight and lowers the price target from $17 to $15.
NeuroPace (NASDAQ:NPCE) raises FY2025 sales outlook from $93.00 million-$97.00 million to $94.00 million-$98.00 million vs $94....
NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.23) b...
NeuroPace, Inc. (NASDAQ:NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, t...
NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today...
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our t...
